User profiles for Daniel E. Furst

Daniel E. Furst

UCLA, Pacific Medical Clinic, Univ. of Washington, University of Florence, Italy
Verified email at furst.us.com
Cited by 105677

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the …

ME Weinblatt, EC Keystone, DE Furst… - Arthritis & …, 2003 - Wiley Online Library
Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal
tumor necrosis factor α antibody, in combination with methotrexate (MTX) in patients with …

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

…, O Distler, Y Allanore, DE Furst… - Arthritis & …, 2013 - Wiley Online Library
Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis

…, RH Shmerling, JR Curtis, DE Furst… - Arthritis & …, 2016 - Wiley Online Library
Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid
arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for …

[HTML][HTML] Infliximab and methotrexate in the treatment of rheumatoid arthritis

…, EW St. Clair, DE Furst… - … England Journal of …, 2000 - Mass Medical Soc
Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial

…, AL Weaver, EC Keystone, DE Furst… - Annals of internal …, 1999 - acpjournals.org
Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

[HTML][HTML] Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

…, DE Yocum, TJ Schnitzer, DE Furst… - … England Journal of …, 2006 - Mass Medical Soc
Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …

[PDF][PDF] 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the …

JA Singh, DE Furst, A Bharat, JR Curtis… - Arthritis care & …, 2012 - Wiley Online Library
The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

…, J O'dell, AM Turkiewicz, DE Furst - Arthritis Care & …, 2008 - Wiley Online Library
Guidelines and recommendations developed and/or endorsed by the American College of
Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and …

[HTML][HTML] Cyclophosphamide versus placebo in scleroderma lung disease

…, J Goldin, MD Roth, DE Furst, E Arriola… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to …

…, G Kerr, C King, G Levy, DE Furst… - Arthritis care & …, 2012 - Wiley Online Library
Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a
foundation of an excess body burden of uric acid, manifested in part by hyperuricemia, which …